Adalvo provides an update on Rifamycin SV MMX, an approved product in the EU, with multiple Marketing Authorizations (MAs) secured.
Rifamycin SV MMX 200mg modified-release tablets is indicated for the treatment of traveler's diarrhea in adults. This product is the first antibiotic engineered with Multi Matrix Technology (MMX®) which allows the antibiotic to be delivered directly into the colon, avoiding unwanted effects on beneficial bacterial flora in the upper gastrointestinal tract.
While demonstrating proven efficacy in robust clinical trials, Rifamycin SV MMX also offers the advantage of simple dosing and performance compared with other antibiotics.
The estimated market opportunity for Rifamycin (Aemcolo®) SV MMX in target territories exceeds $500 million, reflecting its potential to address a significant medical need.
Adalvo's commitment to delivering high-quality differentiated products is evident in the development of Rifamycin SV MMX.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.